Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Biocept, Mission Bio, Bio-Rad, More

Biocept CNSide

Biocept has announced the full commercial launch of CNSide, its cerebrospinal fluid liquid biopsy assay designed to detect and help manage the treatment of cancers that have metastasized to the central nervous system. Initially introduced in January 2020, the test uses Biocept's quantitative tumor cell capture technology, paired with assays to identify actionable molecular treatment targets.

In presentations at recent scientific meetings, Biocept has shared data showing that CNSide could detect tumor cells in about 80 percent of suspect cases, while current cytology methods only capture about 50 percent. The test is currently validated to identify CNS metastases in patients with cancers originating in the lung or breast, but Biocept plans to expand to additional tumor types in the future.


Mission Bio Pharma Assay Development Services

Mission Bio has launched its Pharma Assay Development (PAD) services to help biopharma customers accelerate biomarker discovery and cell and gene therapy development. The PAD team will provide customers with services based on its existing single-cell multiomics technologies as well as early access to services based on new technology innovations, the company said.


Bio-Rad Laboratories SARS-CoV-2 Variant RT-PCR Assays

Bio-Rad Laboratories has launched research-use-only SARS-CoV-2 variant assays to detect variants of concern, including the P1, B1351, and B117 viral variants. The Bio-Rad SARS-CoV-2 Variant RT-PCR Assays are single-tube duplex assays designed to support detection of a specific mutation in the FAM channel and wild-type sequence in the HEX channel using either Droplet Digital PCR or RT-PCR, according to the company's website. The assays may enable laboratories to prioritize samples to send for next-generation sequencing, Bio-Rad noted.


For more new products and services, please visit the New Products page on our website.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.